Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 Janeiro 2024 - 6:01PM
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development, and commercialization of targeted therapies
for women’s cancers, today announced that Sean P. Bohen, M.D.,
President and Chief Executive Officer, will present at the 42nd
Annual J.P. Morgan Healthcare Conference in San Francisco,
California, on Tuesday, January 9, 2024, at 5:15 p.m. PT (8:15 p.m.
ET).
A live webcast of the presentation and any accompanying
presentation materials will be available under the News &
Events section of Olema’s investor relations website at
ir.olema.com. The webcast will be archived for at least 30
days.
About Olema OncologyOlema Oncology is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of targeted therapies for women’s
cancers. Olema’s lead product candidate, palazestrant (OP-1250), is
a proprietary, orally-available small molecule with dual activity
as both a complete estrogen receptor (ER) antagonist (CERAN) and a
selective ER degrader (SERD). It is currently being evaluated both
as a single agent in an ongoing Phase 3 clinical trial, OPERA-01,
and in combination with CDK4/6 inhibitors (palbociclib and
ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with
recurrent, locally advanced or metastatic ER-positive (ER+), human
epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Palazestrant has been granted FDA Fast Track designation for the
treatment of ER+/HER2- metastatic breast cancer that has progressed
following one or more lines of endocrine therapy with at least one
line given in combination with a CDK4/6 inhibitor. Olema is
headquartered in San Francisco and has operations in Cambridge,
Massachusetts. For more information, please visit us at
www.olema.com.
Contact:Geoffrey Mogilner, Vice President, Investor Relations
and Communicationsir@olema.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024